THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB

被引：1
|
作者：
Morand, E. [1 ]
Berglind, A. [2 ]
Sheytanova, T. [2 ]
Tummala, R. [2 ]
Illei, G. [3 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] AstraZeneca, Molndal, Sweden
[3] MedImmune LLC, Gaithersburg, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0001
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [41] LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
    Morand, E. F.
    Van Vollenhoven, R.
    Furie, R.
    Kalunian, K.
    Yavuz, S.
    Abreu, G.
    Lindholm, C.
    Al-Mossawi, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 33 - 34
  • [42] Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan.
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Miyasaka, Nobuyuki
    Sumida, Takayuki
    Mimori, Tsuneyo
    Koike, Takao
    Endo, Kazuhiro
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S253 - S254
  • [43] Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
    Parodis, Ioannis
    Lindblom, Julius
    Levy, Roger A.
    Zen, Margherita
    Cetrez, Nursen
    Gomez, Alvaro
    Oon, Shereen
    Henning, Christine
    Khamashta, Munther
    Quasny, Holly A.
    Chauhan, Deven
    Askanase, Anca
    van Vollenhoven, Ronald
    Nikpour, Mandana
    LANCET RHEUMATOLOGY, 2024, 6 (11): : e751 - e761
  • [44] Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod
    Petri, M. A.
    Martin, R. S.
    Scheinberg, M. A.
    Furie, R. A.
    LUPUS, 2017, 26 (01) : 27 - 37
  • [45] Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
    Parodis, Ioannis
    Lindblom, Julius
    Barturen, Guillermo
    Ortega Castro, Rafaela
    Cervera, Ricard
    Pers, Jacques-Olivier
    Genre Romero, Fernanda
    Hiepe, Falk
    Gerosa, Maria
    Kovacs, Laszlo
    De langhe, Ellen
    Piantoni, Silvia
    Stummvoll, Georg
    Vasconcelos, Carlos
    Vigone, Barbara
    Witte, Torsten
    Alarcon-Riquelme, Marta
    Beretta, Lorenzo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3379 - 3382
  • [46] A STUDY ON THE ACHIEVEMENT OF LUPUS LOW DISEASE ACTIVITY STATE AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FROM THE JUNTENDO UNIVERSITY SLE PROSPECTIVE REGISTRY STUDY
    Matsushita, M.
    Amano, H.
    Nozawa, K.
    Ogasawara, M.
    Tada, K.
    Kempe, K.
    Kusaoi, M.
    Kawamoto, T.
    Minowa, K.
    Ando, S.
    Nemoto, T.
    Abe, Y.
    Hayashi, E.
    Murayama, G.
    Tsukahara, T.
    Yamanaka, K.
    Morimoto, S.
    Yang, K.
    Matsudaira, R.
    Katagiri, A.
    Nakiri, Y.
    Takasaki, Y.
    Yamaji, K.
    Tamura, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 669 - 670
  • [47] BENEFICIAL EFFECTS OF AN ANTI-IFNAR1 MONOCLONAL ANTIBODY ON IMMUNE CELL DYSREGULATION AND COMPLEMENT SYSTEM ABNORMALITIES OF SYSTEMIC LUPUS ERYTHEMATOSUS: AN EXPLORATORY ANALYSIS OF PHASE IIB CLINICAL TRIAL OF ANIFROLUMAB
    Guo, X.
    Wang, L.
    Illei, G.
    Brohawn, P.
    Higgs, B. W.
    White, W. I.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 118 - 118
  • [48] Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
    Parodis, Ioannis
    Lindblom, Julius
    Barturen, Guillermo
    Ortega-Castro, Rafaela
    Cervera, Ricard
    Pers, Jacques-Olivier
    Genre, Fernanda
    Hiepe, Falk
    Gerosa, Maria
    Kovacs, Laszlo
    De Langhe, Ellen
    Piantoni, Silvia
    Stummvoll, Georg
    Vasconcelos, Carlos
    Vigone, Barbara
    Witte, Torsten
    Alarcon-Riquelme, Marta E.
    Beretta, Lorenzo
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (07) : 889 - 900
  • [49] Disease activity and health status (SF-36) in post-menopausal systemic lupus erythematosus: The SELENA trial.
    Petri, M
    Buyon, J
    Skovron, ML
    Kim, M
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1062 - 1062
  • [50] Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3TULIP-1 and TULIP-2 trials of anifrolumab
    Strand, Vibeke
    O'Quinn, Sean
    Furie, Richard A.
    Morand, Eric F.
    Kalunian, Kenneth C.
    Schwetje, Erik G.
    Abreu, Gabriel
    Tummala, Raj
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E198 - E207
12345